Publications by authors named "E Bailon"
Article Synopsis
- Increased angiogenesis in chronic lymphocytic leukemia (CLL) is linked to advanced disease, with CLL cells showing a pro-angiogenic gene expression pattern influenced by their environment.
- MMP-9, a component of the microenvironment, was found to enhance MMP-9 expression and secretion in CLL cells, leading to increased endothelial cell proliferation.
- MMP-9 also altered the expression of angiogenic-related genes, particularly decreasing TSP-1 and increasing VEGF, by involving specific molecular pathways, highlighting its role in CLL pathology.
Article Synopsis
- α4β1 integrin and VEGFR2 work together as a receptor complex that interacts with VEGF in chronic lymphocytic leukemia (CLL) cells.
- This interaction suggests that α4β1 integrin has a new and significant role in the development of CLL.
- The findings highlight how understanding these receptors could lead to better insights into CLL pathology and potential treatments.
Article Synopsis
- MMP-9 plays a significant role in the pathology of Chronic Lymphocytic Leukemia (CLL) by regulating cell survival, migration, and inducing cell arrest when expressed at high levels.
- A study identified that MMP-9 alters the gene expression of specific genes in CLL cells, notably including CD99, which affects cell adhesion and migration.
- The research highlights CD99 as a new therapeutic target that, when influenced by MMP-9, regulates CLL cell behavior and could lead to new treatment strategies.
A catalytically inactive gelatinase B/MMP-9 mutant impairs homing of chronic lymphocytic leukemia cells by altering migration regulatory pathways.
Elvira Bailón Noemí Aguilera-Montilla Alejandra Gutiérrez-González Estefanía Ugarte-Berzal Philippe E Van den Steen
Biochem Biophys Res Commun
January 2018
Article Synopsis
- Researchers found that MMP-9, when overexpressed, hinders the movement of chronic lymphocytic leukemia (CLL) cells, leading to studies on a mutant form of MMP-9 that doesn't break down proteins (MMP-9MutE).
- In mouse models, these MMP-9MutE cells showed reduced ability to migrate to key areas like the spleen and bone marrow compared to control cells.
- The study identified changes in cellular signaling pathways; MMP-9MutE cells had higher levels of PTEN and lower p-ERK, indicating that non-proteolytic functions of MMP-9 are important in CLL cell migration and may affect disease progression.
Article Synopsis
- CLL is currently an incurable disease, but arsenic trioxide (ATO) shows promise as an effective therapy by inducing cell death in CLL cells.
- ATO affects gene expression related to oxidative stress, notably increasing the levels of the gene HMOX1 and the protein MMP-9, which are involved in the response to treatment.
- HMOX1 has a pro-apoptotic role that enhances the cytotoxic effects of ATO, making it a potential new therapeutic target when combined with ATO for CLL treatment.